8-K: Scholar Rock Reports 2025 Results, Apitegromab BLA Update

Scholar Rock reported full-year 2025 financial results, provided an update on its apitegromab regulatory pathway, and secured a new $550 million debt facility.

Summary

• Net loss for the fourth quarter ended December 31, 2025, was $91.0 million, compared to $66.5 million for the same period in 2024.
• Full-year 2025 net loss was $377.9 million, an increase from $246.3 million for the full year 2024.
• Cash, cash equivalents, and marketable securities totaled $367.6 million as of December 31, 2025.
• Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026, contingent on a successful FDA reinspection of Catalent Indiana, LLC.
• The FDA completed a constructive meeting with Catalent Indiana, with discussion of remediation progress and no additional corrective actions requested.
• The European Medicines Agency (EMA) decision on the apitegromab Marketing Authorisation Application (MAA) is expected in mid-2026, with European launch planned for the second half of 2026, starting with Germany.
• Scholar Rock secured a new debt facility providing up to $550 million in non-dilutive capital to support apitegromab commercialization and pipeline advancement.
• Development activities for a second U.S.-based fill-finish facility are progressing, with a supplemental BLA (sBLA) expected later in 2026.
• Enrollment and patient dosing continue in the Phase 2 OPAL study for apitegromab in infants and toddlers with SMA.
• Development of a subcutaneous formulation of apitegromab is ongoing, following completion of a Phase 1 study in healthy volunteers.
• The Phase 2 FORGE trial for apitegromab in facioscapulohumeral muscular dystrophy (FSHD) is on track for initiation in mid-2026.
• Dosing continues in a Phase 1 healthy volunteer study for SRK-439, with topline data expected in the second half of 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased, the progress on apitegromab's regulatory path (constructive FDA meeting, EMA review) and the significant non-dilutive funding are strong positives, partially offset by the continued contingency on facility reinspection.

Positives

• A constructive FDA meeting with Catalent Indiana occurred, with no additional corrective actions requested, which is a positive step towards BLA resubmission for apitegromab.
• The EMA review for apitegromab's Marketing Authorisation Application is ongoing, with a decision anticipated in mid-2026 and a European launch expected in H2 2026.
• Secured a new non-dilutive debt facility of up to $550 million, significantly strengthening the company's financial position to fund commercialization and pipeline programs.
• Advancing a second fill-finish facility for apitegromab to enhance supply continuity and support future commercial demand.
• Continued progress in the pipeline with ongoing Phase 2 OPAL study for SMA, development of a subcutaneous apitegromab formulation, and planned initiation of the Phase 2 FORGE trial for FSHD in mid-2026.
• Dosing continues in the Phase 1 healthy volunteer study for SRK-439, with topline data expected in H2 2026, indicating pipeline advancement.

Negatives

• Net loss for the fourth quarter ended December 31, 2025, increased to $91.0 million from $66.5 million in the prior year period.
• Full-year 2025 net loss significantly increased to $377.9 million from $246.3 million in 2024.
• General and administrative expenses more than doubled in Q4 2025 to $45.0 million from $19.0 million in Q4 2024, and for the full year to $176.2 million from $67.5 million.
• Research and development expenses for the full year 2025 increased to $208.4 million from $184.5 million in 2024.
• The apitegromab BLA resubmission is still contingent on a successful FDA reinspection of the Catalent Indiana facility, indicating a continued delay in the final regulatory step.

Risks

• Preclinical and clinical data, including results from the Phase 3 SAPPHIRE trial, may not be sufficient to support regulatory approval.
• Preclinical and clinical data may not be predictive of, inconsistent with, or more favorable than, data generated from future or ongoing clinical trials.
• Uncertainty whether the FDA will accept the remediations to the Novo Nordisk Bloomington Indiana fill-finish facility.
• Uncertainty regarding the timely resubmission of the BLA and whether the updated BLA will be sufficient to support regulatory approval.
• Ability to manage expenses or provide the financial support, resources, and expertise necessary to identify and develop product candidates on the expected timeline.
• Information provided or decisions made by regulatory authorities could impact timelines or outcomes.
• Competition from third parties that are developing products for similar uses.
• Ability to obtain, maintain, and protect intellectual property.
• Dependence on third parties for development and manufacture of product candidates, including supply for clinical trials.

Future Outlook

Scholar Rock anticipates apitegromab BLA resubmission and U.S. launch in 2026, contingent on successful FDA reinspection of Catalent Indiana. The EMA decision on apitegromab is expected mid-2026, with European launch in H2 2026. The company plans to submit an sBLA for a second fill-finish facility later in 2026 and expects to initiate the Phase 2 FORGE trial for FSHD in mid-2026. Topline data for the SRK-439 Phase 1 study is expected in H2 2026.

Management Comments

• "Our highest priority is to serve children and adults living with SMA by bringing apitegromab through the regulatory review process as quickly as possible."
• "We are encouraged by the FDAs continued engagement and shared sense of urgency as Novo Nordisk works expeditiously to remediate its Catalent Indiana facility."
• "We are ready to resubmit our apitegromab BLA following successful reinspection of the site by the FDA."
• "As we prepare to usher in the next phase of innovation for patients with SMA, we continue to strengthen our financial position while aggressively advancing our pipeline and expect 2026 to be a transformative year for Scholar Rock."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in rare diseases like SMA and FSHD, is characterized by high R&D costs and significant regulatory hurdles. Scholar Rock's focus on myostatin biology positions it in a competitive but high-potential therapeutic area. The reliance on third-party manufacturing (Catalent Indiana) highlights a common industry risk, where supply chain and facility compliance can impact critical regulatory timelines. The securing of a substantial non-dilutive debt facility is a strategic move to fund commercialization and pipeline development without immediate equity dilution, a common approach for companies nearing commercialization with significant capital needs.

Stakeholder Impact

• Shareholders: Potential for significant value creation if apitegromab gains approval and commercial success, but continued losses and regulatory contingencies pose risks. The non-dilutive debt facility is favorable.
• Patients (SMA/FSHD): Closer to potential new treatment options with apitegromab's regulatory progress and pipeline advancement.
• Employees: Continued investment in commercial team expansion and R&D suggests job stability and growth opportunities.
• Creditors (Blue Owl Capital): New debt facility provides a structured return, contingent on company milestones.
• Suppliers (Catalent Indiana): Under pressure to complete remediation for BLA resubmission.

Next Steps

• Successful FDA reinspection of Catalent Indiana facility.
• Resubmission of apitegromab BLA to the FDA.
• U.S. launch of apitegromab following FDA approval in 2026.
• EMA decision on apitegromab MAA in mid-2026.
• European launch of apitegromab in H2 2026, starting with Germany.
• Additional manufacturing runs at the second fill-finish facility through Q2 2026.
• Submission of a supplemental BLA (sBLA) for the second fill-finish facility later in 2026.
• Continued enrollment and patient dosing in the Phase 2 OPAL study for SMA.
• Planned FDA and EMA regulatory engagements for subcutaneous apitegromab.
• Initiation of Phase 2 FORGE trial for FSHD in mid-2026.
• Topline data from Phase 1 healthy volunteer study for SRK-439 in H2 2026.
• Drawdown of an additional $100 million from the debt facility in Q1 2026.

Key Dates

Recommendation

While Scholar Rock reported increased net losses and expenses, the progress on apitegromab's regulatory pathway, including a constructive FDA meeting and ongoing EMA review, provides a clearer, albeit still contingent, path to market. The significant non-dilutive debt facility strengthens the company's financial position to support commercialization and pipeline development. The stock presents a mixed risk-reward profile, warranting a "hold" as investors await critical regulatory approvals and commercial launch data.

Keywords

Scholar Rock, SRRK, Spinal Muscular Atrophy, SMA, Apitegromab, Myostatin Inhibitor, Biopharmaceutical, Rare Disease, FSHD, Facioscapulohumeral Muscular Dystrophy, Clinical Trials, FDA Approval, EMA Approval, Drug Development, Biologics License Application, BLA, Financial Results, Debt Facility, Catalent Indiana, SRK-439